[
  {
    "ts": "2025-12-30T12:32:00+00:00",
    "headline": "Should You Continue to Hold EXAS Stock in Your Portfolio Now?",
    "summary": "Exact Sciences is investing heavily in R&D and commercial capabilities to boost Cologuard adoption, but competition and macro pressures cloud the outlook.",
    "url": "https://finance.yahoo.com/news/continue-hold-exas-stock-portfolio-123200393.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "c3cd601c-d075-3ec1-894e-29b826405163",
      "content": {
        "id": "c3cd601c-d075-3ec1-894e-29b826405163",
        "contentType": "STORY",
        "title": "Should You Continue to Hold EXAS Stock in Your Portfolio Now?",
        "description": "",
        "summary": "Exact Sciences is investing heavily in R&D and commercial capabilities to boost Cologuard adoption, but competition and macro pressures cloud the outlook.",
        "pubDate": "2025-12-30T12:32:00Z",
        "displayTime": "2025-12-30T12:32:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7qxsqrZM8ueKEZZaMBimmA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/z_Y9s.nod8y.0SuZhzp3mg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/continue-hold-exas-stock-portfolio-123200393.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/continue-hold-exas-stock-portfolio-123200393.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EXAS"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-30T13:06:00+00:00",
    "headline": "Should Myriad Genetics Stock Stay in Your Portfolio Right Now?",
    "summary": "MYGN shows growth potential from new genetic test launches and a refreshed CCC strategy, but revenue pressure from GeneSight coverage loss remains a drag.",
    "url": "https://finance.yahoo.com/news/myriad-genetics-stock-stay-portfolio-130600013.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "0a4ad1b6-1a65-3364-8e69-3a4b76d84879",
      "content": {
        "id": "0a4ad1b6-1a65-3364-8e69-3a4b76d84879",
        "contentType": "STORY",
        "title": "Should Myriad Genetics Stock Stay in Your Portfolio Right Now?",
        "description": "",
        "summary": "MYGN shows growth potential from new genetic test launches and a refreshed CCC strategy, but revenue pressure from GeneSight coverage loss remains a drag.",
        "pubDate": "2025-12-30T13:06:00Z",
        "displayTime": "2025-12-30T13:06:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/myriad-genetics-stock-stay-portfolio-130600013.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/myriad-genetics-stock-stay-portfolio-130600013.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MYGN"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]